• No results found

18 results with keyword: 'prevalence brca mutations young triple negative breast cancer'

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

The decision to offer genetic testing to a breast cancer patient is usually based on her family history, but in the absence of a family history of cancer, some women may qualify

Protected

N/A

5
0
0
2021
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

In studies with selected patients referred for BRCA genetic testing, the frequency of TNBC has been reported to be 57% in BRCA1 mutation carriers and 23% in BRCA2 mutation

Protected

N/A

8
0
0
2021
Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features

In unselected triple negative breast cancers, around 19% mutations were reported in the BRCA1/2 genes including also scattered somatic mutations (15% in BRCA and 3.9% in BRCA2

Protected

N/A

12
0
0
2021
FOLD A Calibration Program for the Analysis of Quasi Elastic Neutron Scattering Data  EUR 4516

A Fortran IV computer program has been written which gives a means of calibrating the quasi-elastic peaks obtained from the time-of-flight data of the ISPRA-1 Double

Protected

N/A

38
0
0
2020
PubMedCentral-PMC5156592.pdf

Pathological complete response (pCR) rates after carboplatin- containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast

Protected

N/A

22
0
0
2020
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients

BRCA1 gene [19, 20] and evaluation limited to small- range mutations [16, 21, 22]. In order to determine the utility of genetic testing for BRCA1 and BRCA2 germ- line mutations

Protected

N/A

10
0
0
2021
showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles

TNBC: triple negative breast cancer; TNBCs: triple negative breast cancer patients; NAC: neoadjuvant chemotherapy; PD: progressive disease; TILs: tumor

Protected

N/A

11
0
0
2020
Triple-Negative Breast Cancer

triple-negative breast cancers need different types of treatments because they are estrogen receptor-negative, progesterone receptor-negative and HER2 negative.. Med- icines

Protected

N/A

16
0
0
2021
Triple-Negative Breast Cancer

Even some women who have had breast cancer do not understand the differences between triple-negative breast cancers and breast cancers that are hormone receptor-positive or

Protected

N/A

15
0
0
2021
Triple Negative Breast Cancer: Incidence Rates; Phenotype, Demographic, and Treatment Characteristics; Model for Risk Prediction Among Women of Color

Triple Negative Breast Cancer: Incidence Rates; Phenotype, Triple Negative Breast Cancer: Incidence Rates; Phenotype, Demographic, and Treatment Characteristics; Model for Risk

Protected

N/A

199
0
0
2021
Triple-Negative Breast Cancer

Even some people who have had breast cancer do not understand the differences between triple- negative breast cancers and breast cancers that are hormone receptor-positive

Protected

N/A

31
0
0
2021
Triple negative breast cancer

placebo-controlled, phase 2b study evaluating the effi cacy and safety of sorafenib in combination with paclitaxel as a fi rst line therapy in patients with locally recurrent

Protected

N/A

9
0
0
2020
BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer

Childless participants 18 to 30 years old belonging to hereditary breast/ovarian cancer (HBOC) families and tested for BRCA mutations (positive or negative), but without

Protected

N/A

9
0
0
2020
Treating Triple-Negative Breast Cancer: Where Are We?

TNT: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA 1/2 breast

Protected

N/A

11
0
0
2021
African ancestry and higher prevalence of triple negative breast cancer

METHODS: African American and white American women with invasive cancer diagnosed at the Henry Ford Health System comprised the primary study population, and Ghanaian patients

Protected

N/A

7
0
0
2020
Retention and graduation of Australian Aboriginal and Torres Strait Islander students in initial teacher education

While some teacher education programs had reasonable enrolment of Indigenous students commensurate with the percentage of Indigenous people in their state, the scans

Protected

N/A

6
0
0
2021
Medical Research Archives. Volume 4 Issue 6 Targeting triple-negative breast cancer: optimizing therapeutic outcomes – UPDATE

Key Words: androgen receptor, breast cancer, breast cancer molecular subtypes, cancer treatment, immune checkpoint blockade, targeted therapy, triple-negative

Protected

N/A

22
0
0
2022
MAATY ONE ARRIVAL(RNAV)

KTPA LANDING SOUTH: Continue track to SCLOP, proceed direct FADDI, intercept Rwy 1L final approach course, conduct approach.. KTPA LANDING NORTH: Continue track to FELOM,

Protected

N/A

6
0
0
2021

Upload more documents and download any material studies right away!